comparemela.com

Latest Breaking News On - Natalies callander - Page 1 : comparemela.com

New, Emerging Treatment Options for Patients With Multiple Myeloma

In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma.

United statesNatalies callanderShajik kumarAbbvie incUniversity of wisconsin carbone cancer centerJanssen biotech incMayo clinic comprehensive cancer centerBristol myers squibbNational comprehensive cancer networkNational comprehensive cancer network annualWisconsin carbone cancer centerJanssen biotech

Novel Agents Highlight Changes in Myeloma Field

Leading investigators in the multiple myeloma field discuss the latest clinical trial findings, many of which were presented during the 2023 ASCO Annual Meeting.

United statesSusan balElizabeth betsy odonnellNatalies callanderAlfred garfallJoshua richterStage developmentDuring the peer exchangeRegeneron pharmaceuticals incPfizer incJanssen pharmaceutical companies of johnsonOnclive peer exchangeBristol myers squibbAmerican society of clinical oncologyLegend biotech corporationJanssen biotech inc

Dr Callander on Ongoing and Future Clinical Trials in Multiple Myeloma at Carbone Cancer Center

Natalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma.

University of wisconsinUnited statesNatalies callanderDivision of hematologyCarbone cancer centerUniversity of wisconsin school medicineDepartment of medicinePublic healthMedical oncologyPalliative careWisconsin schoolUniversity of wisconsin school medicine and public healthUniversity of wisconsin carbone cancer centerMaster trialPatients with multiple myeloma

Dr Callander on Investigational Maintenance Regimens in Multiple Myeloma

Natalie S. Callander, MD, discusses the significance of the phase 3 ATLAS, phase 2 FORTE, and phase 2 MASTER trials in patients with multiple myeloma.

University of wisconsinUnited statesPublic healthDivision of hematologyUniversity of wisconsin school medicineDepartment of medicineMedical oncologyPalliative careWisconsin schoolNatalies callanderUniversity of wisconsin school medicine and public healthUniversity of wisconsin carbone cancer centerAtlas trialForte trialMaster trialPatients with multiple myeloma

Characteristics of Relapse Affect Treatment Choices in Multiple Myeloma

Natalie S. Callander, MD, director of the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.

United statesNatalies callanderNational comprehensive cancer networkNational cancer instituteAmerican society of hematologyAmerican societyMultiple myelomaClinical guidelinesCart cell therapyMonoclonal antibodies

vimarsana © 2020. All Rights Reserved.